Lidocaine is widely used as a local anesthetic for alleviation of post-operative pain and for management of acute and chronic painful conditions. Although several approaches are currently used to prolong the duration of action, an effective strategy to achieve neural blockage for several hours remains to be identified. In this study, a lidocaine-loaded Pluronic® F68-reduced graphene oxide hydrogel was developed to achieve sustained release of lidocaine. Fourier transform infrared spectroscopy, X-ray diffraction, and Raman spectroscopy confirmed the synthesis of Pluronic® F68-reduced graphene oxide. Transmission electron microscopy showed wrinkled, flat nanosheets with micelles attached. The developed hydrogel showed desirable pH, viscosity, adhesiveness, hardness, and cohesiveness for topical application. The ex vivo release study demonstrated the ability of the Pluronic® F68-reduced graphene oxide hydrogel to prolong release up to 10 h, owing to the strong π–π interactions between the graphene oxide and the lidocaine. In comparison with a commercial lidocaine ointment, the developed graphene oxide hydrogel showed sustained anesthetic effect in the radiant heat tail flick test and sciatic nerve block model. Thus, this study demonstrates the potential of using Pluronic® F68-reduced graphene oxide nanocarriers to realize prolonged effects of local anesthesia for effective pain management.
CarvalhoGNikkhahGSamiiM.Pain management after post-traumatic brachial plexus lesions. Conservative and surgical therapy possibilities. Der Orthopade1997;
26: 621–625.
2.
GordonSMMischenkoAVDionneRA.Long-acting local anesthetics and perioperative pain management. Dent Clin North Am2010;
54: 611–620.
3.
MarkmanJDPhilipA.Interventional approaches to pain management. Anesthesiol Clin2007;
25: 883–898.
4.
GolzariSESoleimanpourHMahmoodpoorA, et al.
Lidocaine and pain management in the emergency department: a review article. Anesthesiol Pain Med2014;
4: 1–12.
5.
Epstein-BarashHShichorIKwonAH, et al.
Prolonged duration local anesthesia with minimal toxicity. Proc Natl Acad Sci USA2009;
106: 7125–7130.
6.
MoorePAHershEV.Local anesthetics: pharmacology and toxicity. Dent Clin North Am2010;
54: 587–599.
7.
SiskAL.Long-acting local anesthetics in dentistry. Anesth Prog1992;
39: 53–59.
8.
MalamedSF.Local anesthetics: dentistry’s most important drugs, clinical update.Calif Dent Assoc2006;
6: 1–12.
9.
LehrVTTaddioA.Topical anesthesia in neonates: clinical practices and practical considerations. Semin Perinatol2007;
31: 323–329.
10.
OgleOEMahjoubiG.Local anesthesia: agents, techniques, and complications. Dent Clin North Am2012;
56: 133–148.
11.
GrantGJBansinathM.Liposomal delivery systems for local anesthetics. Reg Anesth Pain Med2001;
26: 61–69.
12.
WakiyamaNJuniKNakanoM.Preparation and evaluation in vitro of polylactic acid microspheres containing local anesthetics. Chem Pharm Bull (Tokyo)1981;
29: 3363–3368.
13.
KohaneDSSmithSELouisDN, et al.
Prolonged duration local anesthesia from tetrodotoxin-enhanced local anesthetic microspheres. Pain2003;
104: 415–421.
14.
PandeySSwamySVGuptaA, et al.
Multiple response optimisation of processing and formulation parameters of pH sensitive sustained release pellets of capecitabine for targeting colon. J Microencapsul2018;
35: 259–271.
15.
BoedekerBHLojeskiEWKlineMD, et al.
Ultra-long-duration local anesthesia produced by injection of lecithin‐coated tetracaine microcrystals.J Clin Pharmacol1994;
34: 699–702.
16.
MaulviFAParmarRJDesaiAR, et al.
Tailored gatifloxacin Pluronic® F-68-loaded contact lens: addressing the issue of transmittance and swelling. Int J Pharm2020;
581: 119279.
17.
JunyaprasertVBBoonmePSongkroS, et al.
Transdermal delivery of hydrophobic and hydrophilic local anesthetics from o/w and w/o Brij 97-based microemulsions. J Pharm Pharm Sci2007;
10: 288–298.
18.
JunyaprasertVBBoonmePWursterDE, et al.
Aerosol OT microemulsions as carriers for transdermal delivery of hydrophobic and hydrophilic local anesthetics. Drug Deliv2008;
15: 323–330.
19.
MaulviFAPillaiLVPatelKP, et al.
Lidocaine tripotassium phosphate complex laden microemulsion for prolonged local anaesthesia: in vitro and in vivo studies. Colloids Surf B Biointerfaces2020;
185: 110632.
20.
BeiranvandSEatemadiAKarimiA.New updates pertaining to drug delivery of local anesthetics in particular bupivacaine using lipid nanoparticles. Nanoscale Res Lett2016;
11: 307–310.
21.
de PaulaECeredaCMFracetoLF, et al.
Micro and nanosystems for delivering local anesthetics. Expert Opin Drug Deliv2012;
9: 1505–1524.
22.
MollerRCovinoBG.Cardiac electrophysiologic properties of bupivacaine and lidocaine compared with those of ropivacaine, a new amide local anesthetic. Anesthesiology1990;
72: 322–329.
23.
Abou-OkeilARehanMEl-SawyS, et al.
Lidocaine/β-cyclodextrin inclusion complex as drug delivery system. Eur Polym J2018;
108: 304–310.
24.
Pipa-VallejoAGarcía-Pola-VallejoMJ.Local anesthetics in dentistry, Medicina oral. Med Oral Patol Oral Cir Bucal2004;
9: 440–445.
25.
YouPYuanRChenC.Design and evaluation of lidocaine-and prilocaine-coloaded nanoparticulate drug delivery systems for topical anesthetic analgesic therapy: a comparison between solid lipid nanoparticles and nanostructured lipid carriers, drug design. Drug Des Devel Ther2017;
11: 2743–2752.
26.
de PaulaECeredaCTofoliGR, et al.
Drug delivery systems for local anesthetics. Recent Pat Drug Deliv Formul2010;
4: 23–34.
27.
JohnsonAPGangadharappaHPramodK.Graphene nanoribbons: a promising nanomaterial for biomedical applications. J Control Release2020;
325: 141–162.
28.
RaslanAdel BurgoLSCirizaJ, et al.
Graphene oxide and reduced graphene oxide-based scaffolds in regenerative medicine. Int J Pharm2020;
580: 119226.
29.
MiaoWShimGKangCM, et al.
Cholesteryl hyaluronic acid-coated, reduced graphene oxide nanosheets for anti-cancer drug delivery. Biomaterials2013;
34: 9638–9647.
30.
ShiXWangYSunH, et al.
Heparin-reduced graphene oxide nanocomposites for curcumin delivery: in vitro, in vivo and molecular dynamics simulation study. Biomater Sci2019;
7: 1011–1027.
31.
MaDLinJChenY, et al.
In situ gelation and sustained release of an antitumor drug by graphene oxide nanosheets. Carbon2012;
50: 3001–3007.
32.
WangRGanJLiR, et al.
Controlled delivery of ketamine from reduced graphene oxide hydrogel for neuropathic pain: in vitro and in vivo studies. J Drug Deliv Sci Technol2020;
60: 101964.
33.
LiQLiFQiX, et al.
Pluronic® F127 stabilized reduced graphene oxide hydrogel for the treatment of psoriasis: in vitro and in vivo studies. Colloids Surf B Biointerfaces2020;
195: 111246.
34.
LuoSJinSYangT, et al.
Sustained release of tulobuterol from graphene oxide laden hydrogel to manage asthma. J Biomater Sci2020; 2: 1–12.
35.
FangC-LA Al-SuwayehSFangJ-Y.Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol2013;
7: 41–55.
36.
BakonyiMGácsiAKovácsA, et al.
Following-up skin penetration of lidocaine from different vehicles by Raman spectroscopic mapping. J Pharm Biomed Anal2018;
154: 1–6.
37.
CherianRSSandemanSRayS, et al.
Green synthesis of pluronic stabilized reduced graphene oxide: chemical and biological characterization. Colloids Surf B Biointerfaces2019;
179: 94–106.
38.
ShahriaryLAthawaleAA.Graphene oxide synthesized by using modified hummers approach. Int J Renew Energy Environ Eng2014;
2: 58–63.
39.
AlamSNSharmaNKumarL.Synthesis of graphene oxide (GO) by modified hummers method and its thermal reduction to obtain reduced graphene oxide (rGO). Graphene2017;
6: 1–18.
40.
PaulchamyBArthiGLigneshB.A simple approach to stepwise synthesis of graphene oxide nanomaterial. Nanomed Nanotechnol2015;
6: 1–12.
41.
AbdolhosseinzadehSAsgharzadehHKimHSJSr.Fast and fully-scalable synthesis of reduced graphene oxide. Sci Rep2015;
5: 10160.
42.
YadavMRheeKYParkS.Synthesis and characterization of graphene oxide/carboxymethylcellulose/alginate composite blend films. Carbohydr Polym2014;
110: 18–25.
43.
StobinskiLLesiakBMalolepszyA, et al.
Graphene oxide and reduced graphene oxide studied by the XRD, TEM and electron spectroscopy methods. J Electron Spectrosc Relat Phenom2014;
195: 145–154.
44.
KrishnamoorthyKVeerapandianMMohanR, et al.
Investigation of Raman and photoluminescence studies of reduced graphene oxide sheets. Appl Phys A2012;
106: 501–506.
45.
ShalabyANihtianovaDMarkovP, et al.
Structural analysis of reduced graphene oxide by transmission electron microscopy. Bulg Chem Commun2015;
47: 291–295.
46.
MaulviFAParmarRJShuklaMR, et al.
Plackett-Burman design for screening of critical variables and their effects on the optical transparency and swelling of gatifloxacin-Pluronic-loaded contact lens. Int J Pharm2019;
566: 513–519.
47.
JanaSMannaSNayakAK, et al.
Carbopol gel containing chitosan-egg albumin nanoparticles for transdermal aceclofenac delivery. Colloids Surf B Biointerfaces2014;
114: 36–44.
48.
AhadAAqilMAliA.Investigation of antihypertensive activity of carbopol valsartan transdermal gel containing 1, 8-cineole. Int J Biol Macromol2014;
64: 144–149.
49.
PandeySSMaulviFAPatelPS, et al.
Cyclosporine laden tailored microemulsion-gel depot for effective treatment of psoriasis: in vitro and in vivo studies. Colloids Surf B Biointerfaces2020;
186: 110681.,
50.
HurlerJEngeslandAPoorahmary KermanyB, et al.
Improved texture analysis for hydrogel characterization: gel cohesiveness, adhesiveness, and hardness. J Appl Polym Sci2012;
125: 180–188.
51.
SolimanSMMalakNAEl-GazayerlyON, et al.
Formulation of microemulsion gel systems for transdermal delivery of celecoxib: in vitro permeation, anti-inflammatory activity and skin irritation tests. Drug Discov Ther2010;
4: 459–471.
52.
ZhangLHuangTBiJ, et al.
Long-Term toxicity study of topical administration of a highly-stable rh-aFGF Carbomer 940 hydrogel in a rabbit skin wound model. Front Pharmacol2020;
11: 58–65.
53.
ZhaoZLianYZhuY, et al.
Depot lidocaine-loaded microemulsion for prolonged local anesthesia: different efficacy model studies. J Drug Deliv Sci Technol2020;
55: 101404.
54.
de AraujoDRCeredaCMBrunettoGB, et al.
Encapsulation of mepivacaine prolongs the analgesia provided by sciatic nerve blockade in mice. Can J Anesth2004;
51: 566–570.
55.
ClogstonJDPatriAK. Zeta potential measurement. In: McNeil S (eds) Characterization of nanoparticles intended for drug delivery. Methods in Molecular Biology (Methods and Protocols), vol 697. Humana Press, 2011, pp. 63–70. https://doi.org/10.1007/978-1-60327-198-1_6
56.
PugliaCSarpietroMGBoninaF, et al.
Development, characterization, and in vitro and in vivo evaluation of benzocaine-and lidocaine-loaded nanostructrured lipid carriers. J Pharm Sci2011;
100: 1892–1899.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
